1. Name and Address of Reporting Person* MORNEAU MICHAEL

   (Last) (First) (Middle)
   C/O VIKING THERAPEUTICS, INC.
   12340 EL CAMINO REAL, SUITE 250
   SAN DIEGO CA 92130

2. Issuer Name and Ticker or Trading Symbol Viking Therapeutics, Inc. [ VKTX ]

3. Date of Earliest Transaction (Month/Day/Year) 01/03/2020

4. If Amendment, Date of Original Filed

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   Director X 10% Owner
   Officer (give title below) VP, Finance and Administration
   Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Code</th>
<th>Amount</th>
<th>(A)</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Stock Option (Right to Buy) | $7.77 | 01/03/2020 | A | 40,000 | 01/03/2021 | 01/03/2030 | Common Stock | 40,000 | $0.00 | 40,000 | D |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Explanation of Responses:
1. 25% of the shares subject to the option will vest on each anniversary of the grant date.

Remarks:

/s/ Michael Morneau 01/03/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.